Satellos Bioscience (MSLE) Total Debt (2024 - 2025)
Satellos Bioscience's (MSLE) quarterly Total Debt came in at $2.3 million in Q4 2025, up 48.75% year-on-year from $1.5 million in Q4 2024, and up 48.75% on a QoQ basis from $1.5 million in Q4 2024.
Satellos Bioscience (MSLE) Total Debt (2024 - 2025) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Total Debt data on file, last reported at $2.3 million in Q4 2025.
- On a quarterly basis, Total Debt rose 48.75% year-over-year to $2.3 million in Q4 2025; TTM through Dec 2025 was $2.3 million, a 48.75% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, changed N/A from the prior year.
- Total Debt for Q4 2025 stood at $2.3 million, up from $1.5 million in the prior quarter.
- Over the last five years, Total Debt for MSLE reached as high as $2.3 million in Q4 2025 and fell as low as $1.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 959.06 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Satellos Bioscience | 175.69 Mn | 175.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 1.52 Mn |